Background: This systematic review will address the efficacy and safety of methotrexate, doxorubicin, and cisplatin (MAP) for the treatment of patients with osteosarcoma.
Introduction
Osteosarcoma is one of the most frequent primary sarcoma of bone among young population. [1] [2] [3] Although it has been reported that its overall prevalence and incidence is rare with only 3 persons per million suffer from this condition annually, its treatment is very tough and tricky. [4] [5] [6] [7] Current treatment strategy usually consists of several weeks of chemotherapy before the surgery, then following by the surgery, and also several weeks of chemotherapy after the surgery. [8] [9] [10] [11] However, the overall outcome results were disappointed and unsatisfied during the past decades. [12] [13] [14] Present standard chemotherapy for the treatment of this disorder is the combination of methotrexate, doxorubicin, and cisplatin, also known as MAP. [15] [16] [17] [18] [19] However, its efficacy is still inconclusive. Furthermore, no systematic review and metaanalysis has been conducted to assess the efficacy and safety of MAP for osteosarcoma. Therefore, in the present protocol of systematic review, we will aim to evaluate the efficacy and safety of MAP for the treatment of osteosarcoma.
Methods

Study registration
This protocol has been registered with PROSPERO (CRD42018120004), and has been reported in according with the Preferred Reporting Items for Systematic Reviews and MetaAnalysis (PRISMA) Protocol statement guidelines. [20] LW and QT have contributed equally to this study.
Ethics and dissemination: No research ethics approval is needed for this study, because no confidential patient data will be utilized in this systematic review. Its results will be published at a peer-reviewed journal or through conference presentations.
This work is supported by the Heilongjiang Provincial Health and Family Planning Commission Research Project (NO.2017-400). Provider just financially supports this study, but does not involve all sections of this study, and does not have conflicts interest with this study.
2.2. Study selection criteria 2.2.1. Study types. Only randomized controlled trials (RCTs) of MAP alone for osteosarcoma will be included. All other study types will not be included, such as reviews, non-clinical trials, case reports, letters, and so on.
Interventions.
Study reporting results of interventions involving MAP alone for osteosarcoma only will be included. The combinations of MAP with other interventions for osteosarcoma treatment will not be included. The control treatment will include any types of interventions, except the MAP.
2.2.3. Population. Patients with osteosarcoma, regardless race, sex, and age will be considered to include in this study.
Outcomes.
The primary outcome is event-free survival. It is defined as the time from random assignment until a first event or censoring at last contact. The secondary outcomes include overall survival (defined as time from random assignment until death resulting from any cause or last contact), quality of life (as measured by any measurement tools, such as 36-Item Short Form Health Survey), and toxicity (any short-or long-term toxicities). (Table 1) and will be applied to other electronic databases. In addition, clinical registration website, and reference lists of potentially related studies will also be retrieved to avoid missing any potential eligible studies.
2.2.6. Study selection. Two independent researchers will conduct the study selection by screening titles and abstracts initially. Then, full texts of potential studies will be further reviewed by reading full papers. All procedures of study selection will be based on the PRISMA flow chart. Any differences between 2 researchers will be solved by a third researcher involved by discussion. The flowchart of study selection is showed in Fig. 1. 
Data extraction and management
Two independent researchers will extract all related data from the available included studies. The extracted information will consist of basic information (authors, published year, location, age, sex, funding, and setting), study methods (study design, sample size, details of randomization, allocation, and blinding), interventions (details of treatments from both groups, such as dosage, treatment duration), and outcomes (including primary, secondary outcomes, and any other measurements). The divergences between 2 researchers will be resolved by a third researcher through consultation. Data obtained from the results of exaction will be entered into excel. Outcome results will be pooled into RevMan software 5.3 (The Cochrane Collaboration, London, UK) for meta-analysis.
Risk of bias assessment
Risk of bias for each included study will be used with the Cochrane Risk of Bias Tool. This tool includes 7 items, and each item is assessed by categorizing with low risk of bias, unclear risk of bias, and high risk of bias. Two independent researchers will evaluate the risk of bias for each included study. Any divisions will also be settled down by a third author invited through discussion.
Measurement of treatment effect
The continuous outcome data will be presented as mean difference (MD) or standardized mean difference (SMD) with 95% confidence intervals (CIs), while the dichotomous outcome data will be presented as risk ratio (RR) with 95% CIs.
Unit of analysis
If the cross-over studies will be included in this study, we will only evaluate the first period of study data.
Missing data
If the included study has missing, insufficient or unclear data, we will contact the original corresponding authors to inquire those data. If those data will not be required, we will just pool and analyze the present available data. In addition, it will also be discussed in the manuscript.
Heterogeneity assessment
In this study, we will utilize the I 2 and chi-squared tests to assess the heterogeneity. The value of I 2 is <50%, heterogeneity is considered as reasonable, while the value of I 2 is >50%, heterogeneity is defined as significant.
Data synthesis
If reasonable heterogeneity is identified, fixed-effect model will be used to pool the data, and the meta-analysis will also be conducted. If the heterogeneity is significant, the random-effect model will be utilized to pool the data. In addition, the subgroup analysis will be performed to identify any potential reasons that may cause heterogeneity. If the heterogeneity is still substantial after the subgroup analysis, then data will not be pooled, and meta-analysis will not be conducted. Instead, a narrative summary will be elaborated.
Subgroup analysis
We will conduct the subgroup analysis if significant heterogeneity will be detected according to the differences of treatments, controls, as well as the outcome assessment tools.
Sensitivity analysis
If the data can be pooled, and meta-analysis can be conducted, then sensitivity analysis will be performed to identify the robustness of pooled results, methodological quality, and missing data of all included studies.
Publication bias
If >10 included studies are available, funnel plot will be used to identify the possible publication bias. [21] Additionally, Egg regression and Begger tests will be utilized to detect the funnel plot asymmetry. [22] 
Discussion
The protocol of this systematic review will utilize rigorous methodology to detect and examine studies reporting the outcomes of MAP for osteosarcoma. No systematic review has previously addressed this issue, although lots of published reviews have explored the issue of MAP for osteosarcoma. Although the potential risk of bias of the included studies may limit the analysis, as well as the power of the results in this systematic review, the data pooled results will provide a better understanding of the efficacy of MAP for patients with osteosarcoma.
This review will provide the first rigorous summary evidence of MAP for osteosarcoma across all published randomized controlled trials. The findings of this systematic review will inform our understanding of the value of MAP in treating osteosarcoma outcomes. This evidence may also provide helpful evidence for clinical practice and health policy-makers for the treatment of osteosarcoma. 
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